
Medicenna Therapeutics Corp. – NASDAQ:MDNA
Medicenna Therapeutics Corp. stock price today
Medicenna Therapeutics Corp. stock price monthly change
Medicenna Therapeutics Corp. stock price quarterly change
Medicenna Therapeutics Corp. stock price yearly change
Medicenna Therapeutics Corp. key metrics
Market Cap | N/A |
Enterprise value | N/A |
P/E | -5.45 |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | 1.58 |
PEG ratio | 0.18 |
EPS | -0.38 |
Revenue | N/A |
EBITDA | -17.95M |
Income | -22.19M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeMedicenna Therapeutics Corp. stock price history
Medicenna Therapeutics Corp. stock forecast
Medicenna Therapeutics Corp. financial statements
Sep 2021 | 0 | -8.17M | |
---|---|---|---|
Dec 2021 | 0 | -4.80M | |
Mar 2022 | 0 | -3.20M | |
Mar 2023 | 0 | -6.00M |
2026 | 1.37M | -23.46M | -1706.42% |
---|---|---|---|
2027 | 600K | -19.55M | -3258.4% |
Analysts Price target
Financials & Ratios estimates
2023-11-03 | -0.05 | -0.05 |
---|
Jun 2022 | 20140000 | 2.14M | 10.66% |
---|---|---|---|
Sep 2022 | 42560000 | 8.64M | 20.31% |
Dec 2022 | 38174000 | 4.94M | 12.96% |
Mar 2023 | 36446000 | 6.96M | 19.1% |
Sep 2021 | -9.33M | 0 | 61K |
---|---|---|---|
Dec 2021 | -6.77M | 10.01M | 3.47M |
Mar 2022 | -2.89M | 0 | 85K |
Mar 2023 | -2.29M | 0 | -189K |
Medicenna Therapeutics Corp. alternative data
Aug 2023 | 16 |
---|---|
Sep 2023 | 16 |
Oct 2023 | 16 |
Nov 2023 | 16 |
Dec 2023 | 16 |
Jan 2024 | 16 |
Feb 2024 | 16 |
Mar 2024 | 16 |
Apr 2024 | 16 |
May 2024 | 16 |
Jun 2024 | 16 |
Jul 2024 | 16 |
Medicenna Therapeutics Corp. other data
Quarter | Transcript |
---|---|
Q3 2023 7 Feb 2023 | Q3 2023 Earnings Call Transcript |
Q2 2023 4 Nov 2022 | Q2 2023 Earnings Call Transcript |
Q1 2023 15 Aug 2022 | Q1 2023 Earnings Call Transcript |
Q4 2022 22 Jun 2022 | Q4 2022 Earnings Call Transcript |
-
What's the price of Medicenna Therapeutics Corp. stock today?
One share of Medicenna Therapeutics Corp. stock can currently be purchased for approximately $0.16.
-
When is Medicenna Therapeutics Corp.'s next earnings date?
Unfortunately, Medicenna Therapeutics Corp.'s (MDNA) next earnings date is currently unknown.
-
Does Medicenna Therapeutics Corp. pay dividends?
No, Medicenna Therapeutics Corp. does not pay dividends.
-
What is Medicenna Therapeutics Corp.'s stock symbol?
Medicenna Therapeutics Corp. is traded on the NASDAQ under the ticker symbol "MDNA".
-
What is Medicenna Therapeutics Corp.'s primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Medicenna Therapeutics Corp.?
Shares of Medicenna Therapeutics Corp. can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does Medicenna Therapeutics Corp. have?
As Jul 2024, Medicenna Therapeutics Corp. employs 16 workers.
-
When Medicenna Therapeutics Corp. went public?
Medicenna Therapeutics Corp. is publicly traded company for more then 7 years since IPO on 13 Nov 2017.
-
What is Medicenna Therapeutics Corp.'s official website?
The official website for Medicenna Therapeutics Corp. is medicenna.com.
-
Where are Medicenna Therapeutics Corp.'s headquarters?
Medicenna Therapeutics Corp. is headquartered at 2 Bloor Street West, Toronto, ON.
-
How can i contact Medicenna Therapeutics Corp.?
Medicenna Therapeutics Corp.'s mailing address is 2 Bloor Street West, Toronto, ON and company can be reached via phone at +41 66485555.
Medicenna Therapeutics Corp. company profile:

Medicenna Therapeutics Corp.
medicenna.comNASDAQ
16
Biotechnology
Healthcare
Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. Its lead product is MDNA55, an interleukin- 4 (IL-4) EC that has completed Phase IIb clinical trial for the treatment of recurrent glioblastoma, as well as preclinical and clinical development stages for the treatment of other brain and non-brain tumors. The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; and MDNA132, an IL-13 Superkine for solid tumors. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, antibodies, cytokines, or other Superkines. The company is headquartered in Toronto, Canada.
Toronto, ON M4W 3E2
CIK: 0001807983
ISIN: CA58490H1073
CUSIP: 58490H107